Knobias Clip Report (9-7-2007)

Submitted from Knobias ClipReport

Power3 Medical Products, Inc.'s (PWRM) common stock has begun trading on the OTCBB. Previously, Power3's common stock traded through the Pink Sheets. The Company also announced that it completed the initial phase of its international validation study of its blood serum biomarker test for Parkinson's diseases. The Company used patient samples provided by The University of Thessaly School of Medicine, in Greece, to replicate previous clinical validation studies completed in the U.S. that demonstrated the blood serum protein biomarker's ability to distinguish between Parkinson's disease patients and normal control subjects.

Steven B. Rash, Chief Executive Officer, commented, "This study proves we are well on our way to commercializing the first ever blood serum proteomic tests for the diagnosis of neurodegenerative diseases. These encouraging Parkinson's test results, and the numerous validation studies that are underway for Alzheimer's disease and similar neurological disorders, confirm our commitment to bringing these tests to market. We believe this test will be a major advance for patients and physicians, as it will offer a means to detect neurodegenerative diseases at their earliest stages without a painful and complicated spinal tap procedure."

Recently, Mr. Rash was President and CFO of Global Water Technologies (GWTR).

Power3 is engaged in the commercialization of protein biomarkers, pathways and mechanisms of diseases through the development of diagnostic tests and drug targets for cancer and neurodegenerative diseases. The Company operates a state-of-the-art CLIA certified proteomics laboratory. Power3 leverages its knowledge of proteomics, the science of protein interactions within living cells, to detect diseases at an early stage.

The Company recently signed an agreement to form a joint venture collaboration with NeoGenomics, Inc. (NGNM) to commercialize Power3's portfolio of 534 biomarkers for a broad range of diseases as the basis of blood-based tests for breast cancer, ALS (Lou Gehrig's Disease), Alzheimer's and Parkinson's Diseases. Power3 will own a minority interest of the new Contract Research Organization, which is expected to be launched in the third or fourth quarter of 2007. As part of the agreement, Power3 will receive $200,000 of working capital from NeoGenomics, and grant NeoGenomics options to increase its equity stake in Power3 up to 60% of the fully diluted shares. NeoGenomics will provide access to cancer samples, management, sales and marketing personnel, laboratory facilities and working capital. NeoGenomics offers testing in cancer genetics, flow cytometry and molecular diagnostics. It has labs in Nashville, Irvine, and Fort Myers, and it services pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States.

Power3 has a collaboration and licensing agreement with BioSite, Inc. to develop antibodies and diagnostic assays for selected target biomolecules. BioSite was acquired by Inverness Medial Innovations, Inc. (IMA), and it is uncertain as to whether or not BioSite will continue with its program. If they discontinue this research effort, it could significantly reduce Power3's cash flows.

As of June 30, 2007, the Company had an accumulated deficit of $10.5 million and cash on hand of $647,000.


Visit 1800blogger to see all of our industry leading blogs